- Home
- IPA vs GOVX Comparison
IPA vs GOVX Comparison
Compare IPA & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- GOVX
- Stock Information
- Founded
- IPA 1983
- GOVX 2001
- Country
- IPA Canada
- GOVX United States
- Employees
- IPA N/A
- GOVX N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- IPA Health Care
- GOVX Health Care
- Exchange
- IPA Nasdaq
- GOVX Nasdaq
- Market Cap
- IPA 18.9M
- GOVX 17.1M
- IPO Year
- IPA 2017
- GOVX N/A
- Fundamental
- Price
- IPA $0.44
- GOVX $2.43
- Analyst Decision
- IPA Strong Buy
- GOVX Strong Buy
- Analyst Count
- IPA 2
- GOVX 5
- Target Price
- IPA $6.00
- GOVX $14.20
- AVG Volume (30 Days)
- IPA 1.1M
- GOVX 3.6M
- Earning Date
- IPA 12-12-2024
- GOVX 11-12-2024
- Dividend Yield
- IPA N/A
- GOVX N/A
- EPS Growth
- IPA N/A
- GOVX N/A
- EPS
- IPA N/A
- GOVX N/A
- Revenue
- IPA $17,441,886.00
- GOVX $3,090,161.00
- Revenue This Year
- IPA $4.33
- GOVX N/A
- Revenue Next Year
- IPA $35.64
- GOVX $565.58
- P/E Ratio
- IPA N/A
- GOVX N/A
- Revenue Growth
- IPA 11.21
- GOVX N/A
- 52 Week Low
- IPA $0.35
- GOVX $1.09
- 52 Week High
- IPA $2.60
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- IPA 40.98
- GOVX 51.87
- Support Level
- IPA $0.40
- GOVX $2.31
- Resistance Level
- IPA $0.53
- GOVX $3.88
- Average True Range (ATR)
- IPA 0.07
- GOVX 0.32
- MACD
- IPA 0.00
- GOVX 0.10
- Stochastic Oscillator
- IPA 37.76
- GOVX 31.92
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, Australia and others. The majority of its revenue is derived from United States of America.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.